PDF herunterladen
Semin Thromb Hemost 2003; 29(6): 575-584
DOI: 10.1055/s-2004-815625
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Impact of Single Nucleotide Polymorphisms of the Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Gene on TAFI Antigen Levels in Healthy Children and Pediatric Oncology Patients

Ralf Knoefler1 , Kathrin Ludwig,1 , Heike Kostka,2 , Eberhard Kuhlisch,3 , Gabriele Siegert2 , Meinolf Suttorp1
  • 1Department of Pediatric Hematology and Oncology, University Hospital of Technical University, Dresden, Germany
  • 2Department of Clinical Chemistry, University Hospital of Technical University, Dresden, Germany
  • 3Department of Medical Statistics, University Hospital of Technical University, Dresden, Germany
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
13. Januar 2004 (online)

    Lizenzen und Reprints

ABSTRACT

The thrombin activatable fibrinolysis inhibitor (TAFI) influences the pathways regulating fibrin formation and deposition. The enormous TAFI plasma level variability present in adults may be explained by a combination of two polymorphisms in the TAFI gene (+1542C>G; 505G>A). We aimed to correlate these two polymorphisms with plasma TAFI antigen concentrations in healthy children and pediatric oncology patients with and without venous thrombosis who were supplied with Broviac central venous catheters. Polymorphisms were detected by restriction fragment length polymorphism (RFLP) analysis of polymerase chain reaction (PCR) amplification, whereas TAFI concentration was determined using a commercial enzyme-linked immunosorbent assay (ELISA). Samples from 57 controls and 67 pediatric patients (11 venous thrombotic complications) were studied. TAFI levels in healthy children and patients were not influenced by gender or age. Compared with the 505GG carriers (wild type), 505AA carriers as well as heterozygous 505GA carriers each exhibited significantly higher TAFI antigen concentrations. In contrast, the lowest TAFI levels were detected in homozygous carriers of the +1542GG polymorphism. A combination of the genotype 505AA (homozygous carrier) and +1542CC (wild type) was present in 13 probands and resulted in the highest TAFI levels. Although in oncologic patients the risk of thrombosis was markedly increased by the heterozygous factor V 1691G>A mutation, the two TAFI polymorphisms investigated exerted no thrombogenic influence.

KEYWORDS

TAFI - polymorphism - thrombosis - oncology - children

REFERENCES

  • 1 Eaton D L, Malloy B E, Tsai S P, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma.  J Biol Chem . 1991;  266 21833-21838
    PubMedSuche in Google Scholar
  • 2 Mosnier L O, von dem Borne A P, Meijers J C, Bouma B N. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.  Thromb Haemost . 1998;  80 829-835
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Bajzar L, Manuel R, Nesheim M E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.  J Biol Chem . 1995;  270 14477-14484
    CrossrefPubMedSuche in Google Scholar
  • 4 Boffa M B, Wang W, Bajzar L, Nesheim M E. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.  J Biol Chem . 1998;  273 2127-2135
    CrossrefPubMedSuche in Google Scholar
  • 5 Wang W, Boffa M B, Bajzar L, Walker J B, Nesheim M E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor.  J Biol Chem . 1998;  273 27176-27181
    CrossrefPubMedSuche in Google Scholar
  • 6 Juhan-Vague I, Morange P E, Aubert H, on behalf of the HIFMECH study group. et al . Plasma thrombin activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.  Arterioscler Thromb Vasc Biol . 2002;  22 867-873
    CrossrefPubMedSuche in Google Scholar
  • 7 Van Tilburg H N, Rosendaal F R, Bertina R M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.  Blood . 2000;  95 2855-2859
    PubMedSuche in Google Scholar
  • 8 Chetaille P, Alessi M C, Kouassi D, Morange P E, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects.  Thromb Haemost . 2000;  83 902-905
    PubMedSuche in Google Scholar
  • 9 Juhan-Vague I, Renucci J F, Grimaux M. et al . Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors.  Arterioscler Thromb Vasc Biol . 2000;  20 2156-2161
    PubMedSuche in Google Scholar
  • 10 Henry M, Aubert H, Morange P E. et al . Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled.  Blood . 2001;  97 2053-2058
    CrossrefPubMedSuche in Google Scholar
  • 11 Miller S A, Dykes D D, Plesky H F. A simple salting out procedure for extracting DNA from human nucleated cells (letter).  Nucleic Acid Res . 1988;  16 1215
    CrossrefPubMedSuche in Google Scholar
  • 12 Kostka H, Kuhlisch E, Schellong S, Siegert S. Polymorphisms in the TAFI gene and the risk of venous thrombosis (in press).  Clin Lab . 2003;  49
    PubMedSuche in Google Scholar
  • 13 Bertina R M, Koelemann F R, Koster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C.  Nature . 1994;  369 64-67
    CrossrefPubMedSuche in Google Scholar
  • 14 Poort S R, Rosendaal F R, Rietsma P H, Bertina R M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.  Blood . 1996;  88 3698-3703
    CrossrefPubMedSuche in Google Scholar
  • 15 Brouwers G J, Vos H L, Leebeek F W. et al . A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels.  Blood . 2001;  98 1992-1993
    CrossrefPubMedSuche in Google Scholar
  • 16 Franco R F, Fagundes M G, Meijers J C. et al . Identification of polymorphisms in the 5′-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.  Haematologica . 2001;  86 510-517
    PubMedSuche in Google Scholar
  • 17 Tregouet D A, Aubert H, Henry M. et al . Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms.  Hum Genet . 2001;  109 191-197
    PubMedSuche in Google Scholar
  • 18 Schroeder V, Chatterjee T, Mehta H. et al . Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography.  Thromb Haemost . 2002;  88 1020-1025
    PubMedSuche in Google Scholar
  • 19 Morange P E, Juhan-Vague I, Scarabin P Y, on behalf of the PRIME study group. et al . Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME study.  Thromb Haemost . 2003;  89 544-560
    PubMedSuche in Google Scholar
  • 20 Morange P E, Aillaud M F, Nicaud V, Henry M, Juhan-Vague I. Ala147Thr and C+1542G polymorphisms in the TAFI gene are not associated with a higher risk of venous thrombosis in FV Leiden carriers.  Thromb Haemost . 2001;  86 1583-1584
    PubMedSuche in Google Scholar
  • 21 Siegert G, Kuhlisch E, Schellong S, Kostka H. Mutations in the TAFI gene and the risk for deep vein thrombosis (abstract).  Ann Hematol . 2003;  82 (suppl 1) (abstract) S82
    PubMedSuche in Google Scholar
  • 22 Kostka H, Schellong S, Kuhlisch E, Siegert S. Mutations in the TAFI gene are not associated with higher risk of venous thrombosis (abstract).  J Lab Med . 2002;  26 530
    PubMedSuche in Google Scholar
  • 23 Bertina R M. Genetic approach to thrombophilia.  Thromb Haemost . 2001;  86 92-103
    PubMedSuche in Google Scholar
  • 24 Martinelli I. Risk factors in venous thromboembolism.  Thromb Haemost . 2001;  86 395-403
    PubMedSuche in Google Scholar
  • 25 Nowak-Göttl U, Koch H G, Aschka I. et al . Resistance to activated protein C (APCR) in children with venous and arterial thromboembolism.  Br J Haematol . 1996;  92 992-998
    CrossrefPubMedSuche in Google Scholar
  • 26 Schobess R, Junker R, Auberger K, Münchow N, Burdach S, Nowak-Göttl U. Factor V G1691A and prothrombin G20210A in childhood spontaneous venous thrombosis-Evidence of an age-dependent thrombotic onset in carriers of factor V G1691A and prothrombin G20210A mutation.  Eur J Pediatr . 1999;  158 (suppl 3) S105-S108
    PubMedSuche in Google Scholar
  • 27 Nowak-Göttl U, Wermes C, Junker R. et al . Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.  Blood . 1999;  93 1595-1599
    PubMedSuche in Google Scholar
  • 28 Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora K W. Clinical relevance of genetic risk factors for thrombosis in pediatric oncology patients with central venous lines.  Eur J Pediatr . 1999;  158 (suppl 3) S143-S146
    CrossrefPubMedSuche in Google Scholar